Application of effect-compartment model to bumetanide-indomethacin interaction in dogs
dc.contributor.author | Fox, Jeffrey L. | en_US |
dc.contributor.author | Lau, Henry S. H. | en_US |
dc.contributor.author | Smith, David E. | en_US |
dc.date.accessioned | 2006-09-11T15:35:21Z | |
dc.date.available | 2006-09-11T15:35:21Z | |
dc.date.issued | 1983-08 | en_US |
dc.identifier.citation | Smith, David E.; Lau, Henry S. H.; Fox, Jeffrey L.; (1983). "Application of effect-compartment model to bumetanide-indomethacin interaction in dogs." Journal of Pharmacokinetics and Biopharmaceutics 11(4): 355-368. <http://hdl.handle.net/2027.42/45030> | en_US |
dc.identifier.issn | 1573-8744 | en_US |
dc.identifier.issn | 0090-466X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45030 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=6668548&dopt=citation | en_US |
dc.description.abstract | Analyses of bumetanide's dose-response relationship have been complicated by the hysteresis observed between the drug's urinary excretion rate and its sodium excretion. This apparent time lag reflects the disequilibrium between the urine concentration and effect compartment (biophase) which occurs during the early distribution phase. In the present article, an expanded pharmaco-dynamic model has been introduced in which the hypothetical effect compartment is linked, by a first-order process (K ue ), to the urine compartment. Drug dissipation from the effect compartment occurs by means of the first-order rate constant , K eo . This representation accommodates bumetanide's luminal site of action in the kidney tubule as well as the drug's temporal component. Application of this model to the bumetanide-indomethacin interaction in dogs is examined. | en_US |
dc.format.extent | 667925 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Effect-compartment Model | en_US |
dc.subject.other | Bumetanide | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Veterinary Medicine | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Indomethacin | en_US |
dc.subject.other | Dose-response Relationship | en_US |
dc.title | Application of effect-compartment model to bumetanide-indomethacin interaction in dogs | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, 48109, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, 48109, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | College of Pharmacy, The University of Michigan, 48109, Ann Arbor, Michigan; Department of Pharmaceutics, College of Pharmacy, The University of Utah, 84112, Salt Lake City, Utah | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 6668548 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45030/1/10928_2005_Article_BF01058955.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF01058955 | en_US |
dc.identifier.source | Journal of Pharmacokinetics and Biopharmaceutics | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.